Sofpironium Bromide Gel Reliable in Treating Excessive Underarm Sweating, finds research

Primary axillary hyperhidrosis is a condition characterized by excessive underarm sweating and has long presented challenges in terms of effective and non-invasive treatments. However, recent study published in the recent issue of The Journal of Dermatological Treatment suggest that sofpironium bromide gel may provide a breakthrough option for patients seeking relief.

This comprehensive review included 5 clinical studies involving a total of 752 patients with primary axillary hyperhidrosis. Sofpironium bromide gel was administered at varying concentrations, predominantly at 5%, with one study exploring 5%, 10%, and 15% formulations. The results demonstrated significant benefits in both symptom control and quality of life improvements.

The patients using the gel experienced a marked reduction in sweating. Between 53.9% and 86.7% of participants reported an improvement in their Hyperhidrosis Disease Severity Scale (HDSS) scores, achieving a score of 1 or 2, indicating mild or no noticeable sweating. Furthermore, the Dermatology Life Quality Index (DLQI) showed substantial improvements for the patients treated with sofpironium bromide when compared to control groups.

The studies also highlighted reductions in the total gravimetric weight of sweat and reported that between 48.2% and 69.1% of patients experienced at least a 1.5-point improvement on the Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) scale. Also, the gel was well-tolerated by patients. While localized mild side effects such as skin irritation were observed, no serious adverse events were reported across the studies, reinforcing the safety profile of this gel.

Hyperhidrosis affects approximately 4.8% of the U.S. population and significantly impacts physical, social, and psychological well-being. The approval of sofpironium bromide gel by the U.S. Food and Drug Administration (FDA) marks a significant step forward in offering a non-invasive and effective treatment for individuals with this condition. Overall, the findings of this study highlight that sofpironium bromide gel is reliable, safe, and effective option for the patients seeking relief from primary axillary hyperhidrosis.

Source:

Odat, R. M., Yousef Aldalati, A., Hammadeh, B. M., Mohammad Hussein, A., Idrees, M., Marzouk, H., Alshwayyat, S., & Hanifa, H. (2025). Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review. The Journal of Dermatological Treatment, 36(1). https://doi.org/10.1080/09546634.2024.2441258